Head-to-head evidence
duvakitug vs MT-201
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: TL1A · full Ulcerative Colitis pipeline
duvakitug
Developed by Teva Pharmaceutical Industries and partners
NCT05499130 · Phase 2b · completed
Randomized, double-blind, placebo-controlled, with the high dose reaching significance (p=.003) and replicating in a Crohn's disease cohort. The low dose was only borderline (p=.050) and the sample size per arm was modest. A well-designed trial with a partial, dose-dependent result is capped at moderate rather than strong. Progressed to Phase 3.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: May 2028 · NCT07184996 (registry estimate)
MT-201
Developed by Mirador Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2027 · NCT07113522 (registry estimate)
Crohn's Disease
Shared mechanism: TL1A · full Crohn's Disease pipeline
duvakitug
Developed by Teva Pharmaceutical Industries and partners
NCT05499130 · Phase 2b · completed
Randomized, double-blind, placebo-controlled, with the high dose reaching significance (p=.003) and replicating in a Crohn's disease cohort. The low dose was only borderline (p=.050) and the sample size per arm was modest. A well-designed trial with a partial, dose-dependent result is capped at moderate rather than strong. Progressed to Phase 3.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: May 2029 · NCT07184931 (registry estimate)
MT-201
Developed by Mirador Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2027 · NCT07113522 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: duvakitug's landscape · MT-201's landscape